Cinqair market report points to growth in severe asthma biologics through 2035

The Business Research Company says the Cinqair, also called Cinqaero, market is set to expand through 2035 as severe eosinophilic asthma treatments shift toward biologics and more targeted care. The report highlights rising asthma prevalence, higher air pollution, and stronger reimbursement as key forces behind demand.

Why it matters: - Cinqair, also known as Cinqaero, sits in a growing category of biologic therapies for severe eosinophilic asthma. - The market outlook matters because treatment demand is rising alongside asthma prevalence, pollution exposure, and broader use of precision respiratory care. - The report points to hospital-based infusion treatment and IL-5 inhibitor adoption as areas that could shape access and care delivery.

What happened: - The Business Research Company released its "Cinqair Or Cinqaero Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035" on Nov. 2, 2026. - The report says the historical market was supported by limits in corticosteroid treatment, better identification of eosinophilic asthma, clinical use of interleukin-5, or IL-5, inhibitors, broader biologic adoption, and specialist-led protocols. - The report forecasts growth from rising asthma cases, more personalized respiratory care, higher reimbursement for biologics, improved patient stratification, and pulmonology specialty networks. - The report also flags rising use of targeted biologics, more IL-5 inhibitor therapy, higher diagnosis rates of eosinophilic asthma, and a stronger focus on reducing asthma flare-ups. - A free sample of the report is available here. - The full report is available here.

The details: - Cinqair, or Cinqaero, refers to reslizumab, a humanized monoclonal antibody used primarily in adults with severe eosinophilic asthma. - The drug blocks IL-5, a molecule involved in eosinophil production. - By inhibiting IL-5, Cinqair lowers eosinophil counts, reduces inflammation, and helps improve lung function. - The report identifies air pollution as a major market driver. - The release cites the U.S. Environmental Protection Agency as reporting in May 2025 that about 66 million tons of pollutants were emitted into the U.S. atmosphere in 2023. - The report also ties demand to the wider rise in biologics, which are complex drugs derived from living organisms. - The release cites an August 2025 report from the U.S. Assistant Secretary for Planning and Evaluation saying biosimilar revenues can vary widely and that regulatory updates may reduce development costs and increase lifetime revenue. - The report says asthma prevalence remains uneven across populations and regions. - The American Lung Association reported in July 2024 that asthma prevalence among Black individuals was 10.3% in 2022, compared with 8.4% among white individuals. - The American Lung Association also reported that adult asthma rates in 2023 ranged from 7.1% in Mississippi to 14.1% in Puerto Rico.

Between the lines: - The report frames Cinqair as part of a broader shift away from one-size-fits-all asthma treatment. - The emphasis on biomarkers, patient stratification, and specialty networks suggests the market is becoming more data-driven and more concentrated in specialist care settings. - North America’s lead position in 2025 likely reflects established healthcare infrastructure and demand for advanced therapies. - Europe’s expected faster growth suggests room for wider biologic adoption across the forecast period.

What's next: - The report says North America held the leading market position in 2025. - Europe is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report set adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, future trend analysis, and updated graphics and tables. - The Business Research Company lists contact details for expert discussions and follow-up inquiries, including Saumya Sahay and Oliver Guirdham.

The bottom line: - Cinqair’s market outlook is tied to a larger biologics shift in severe asthma care, with growth prospects anchored by diagnosis, reimbursement, and rising respiratory disease burden.